Setting a new standard in biosimilars
Who we are
Alvotech is a fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high-quality biosimilar medicines.
Purpose driven culture
Alvotech’s true purpose is to make patients’ lives better by improving access to affordable biosimilar medicines and helping with the sustainability of healthcare systems. We operate on the principle that if there’s a cure, we believe it should be available for everyone and not just the privileged few.
Like to join our team?
Alvotech prides itself on attracting highly experienced industry talent, drawn by its purpose-driven culture. With its strong emphasis on excellence and commitment to improving the lives of patients by making biologics more accessible around the globe, Alvotech strives to promote a culture of diversity and inclusion.
Follow news and programs from Alvotech around the world as they unfold.
Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada
AVT02 Approved for Use in European Union
Research & Development
Our biosimilar assets include various biosimilar monoclonal antibodies that are developed in our four R&D centers located across Europe and are manufactured in our state-of-the-art facility located in Reykjavik, Iceland.
Our state of the art facility is designed and built to meet highest FDA and EMA GMP requirements globally. Alvotech’s primary focus is on safety, compliance and flexibility.
Where we are
The company’s international team includes over 650 scientists and professionals working for Alvotech in multiple locations: our headquarters in Reykjavik, Iceland, our development centers in Germany and Switzerland and our regulatory affairs, governmental policy and legal subsidiary in Virginia, USA.